ERV14 Antibody

What is ERV14 and why is it important in cellular transport?

ERV14, also known as cornichon, belongs to a conserved family of cargo receptors required for the selection and endoplasmic reticulum (ER) export of transmembrane proteins . It functions as a critical component in the early secretory pathway, facilitating the incorporation of membrane proteins into COPII vesicles that transport cargo from the ER to the Golgi apparatus. Research has demonstrated that ERV14 plays a significant role in the proper localization of various plasma membrane transporters .

The protein contains important regulatory domains, with recent studies highlighting the C-terminus as particularly significant. Phosphorylation at serine 134 (S134) appears to regulate ERV14 function, with phosphomimetic mutations (S134D) preventing incorporation into COPII vesicles and affecting downstream cargo transport .

What are the most effective epitopes for ERV14 antibody generation?

When developing antibodies against ERV14, researchers should consider several key epitope regions:

• The C-terminal domain: This region contains the phosphorylation site S134 that regulates ERV14 function and is accessible for antibody binding . Antibodies targeting this region can help distinguish between phosphorylated and non-phosphorylated forms.

• Transmembrane domains: While typically challenging for antibody generation, these regions contain conserved sequences that may serve as unique epitopes.

• N-terminal domain: This region can provide accessibility for antibody binding in native protein conformation.

For detection of post-translational modifications, phospho-specific antibodies targeting the S134 site would be particularly valuable, as research has demonstrated the importance of this site in regulating ERV14 function and COPII vesicle incorporation .

How can I validate the specificity of my ERV14 antibody?

A comprehensive validation approach for ERV14 antibodies should include:

• Western blot analysis using:

  • Wild-type cells expressing ERV14

  • ERV14 knockout (Δerv14) cells as negative control

  • Cells expressing tagged versions of ERV14 (e.g., HA-tagged ERV14)

  • Phosphorylation site mutants (S134A and S134D) to distinguish phospho-forms

• Immunoprecipitation followed by mass spectrometry to confirm target identity

• Immunofluorescence microscopy comparing wild-type and Δerv14 cells, with colocalization studies using known ER and Golgi markers

• Competition assays with purified ERV14 protein to demonstrate binding specificity

Research shows that ERV14 typically displays multiple bands on western blots, particularly when using Zn²⁺-Phos-tag gels, with the upper band corresponding to phosphorylated forms . A properly validated antibody should detect these distinct isoforms.

How can I design an in vitro vesicle budding assay to study ERV14 incorporation using antibodies?

The in vitro vesicle budding assay is a powerful technique to study ERV14 incorporation into COPII vesicles. Based on published protocols, the following methodology is recommended:

• Prepare washed semi-intact cells (SICs) from strains expressing HA-tagged ERV14 (wild-type or phosphorylation mutants) in a Δerv14 background .

• Set up reaction mixtures containing:

  • SICs

  • Purified COPII proteins (Sar1, Sec23-Sec24, Sec13-Sec31)

  • GTP

  • ATP regeneration system

  • B88 buffer

• Include negative controls without COPII proteins to confirm specificity.

• Incubate at 25°C for 30 minutes to allow vesicle formation.

• Separate vesicles from bulk membranes by differential centrifugation:

  • First centrifuge at 24,104 g for 3 minutes at 4°C to pellet SICs

  • Collect supernatant and centrifuge at 100,000 g to pellet vesicles

• Analyze vesicle content by SDS-PAGE and immunoblotting with anti-HA antibody.

• Include controls:

  • Sec61 (negative control, ER resident)

  • Coy1 (positive control, correctly sorted into COPII vesicles)

• Quantify packaging efficiency by comparing vesicle fraction signal to total input (typically set as 10% of total reaction).

Research using this approach has demonstrated that phosphorylation state significantly impacts ERV14 packaging into COPII vesicles .

What methods can I use to study ERV14 localization and trafficking using antibodies?

To comprehensively analyze ERV14 localization and trafficking, combine the following complementary approaches:

• Subcellular fractionation and immunoblotting:

  • Separate ER (P13 fraction) and Golgi (P100 fraction) membranes by differential centrifugation

  • Analyze ERV14 distribution by western blotting with anti-ERV14 antibodies

  • Include controls: Yet3 (ER marker) and Och1 (Golgi marker)

• Fluorescence microscopy:

  • Immunofluorescence with anti-ERV14 antibodies or visualization of ERV14-GFP fusion proteins

  • Colocalization with organelle markers

  • Live-cell imaging to track dynamic movement

• Genetic interaction studies:

  • Combine ERV14 mutations with temperature-sensitive mutations in COPII components (e.g., SEC23, SEC16, SEC31)

  • Analyze growth phenotypes at permissive and restrictive temperatures

Research has shown that wild-type ERV14 distributes relatively equally between ER and Golgi fractions, while the phosphomimetic ERV14 S134D mutant shows preferential retention in the ER fraction (P13), indicating impaired trafficking .

How can I detect and quantify phosphorylated forms of ERV14?

Detecting and quantifying phosphorylated ERV14 requires specialized techniques:

• Phos-tag gel electrophoresis:

  • Use Zn²⁺-Phos-tag gels for separation of phosphorylated and non-phosphorylated forms

  • Research shows two distinct ERV14 isoforms on these gels, with the upper band corresponding to phosphorylated forms

  • Quantify band intensities to determine relative abundance

• Phospho-specific antibodies:

  • Use antibodies specifically raised against phosphorylated S134

  • Validate specificity using S134A (non-phosphorylatable) and S134D (phosphomimetic) mutants

• Mass spectrometry:

  • Immunoprecipitate ERV14 using specific antibodies

  • Analyze phosphorylation sites by LC-MS/MS

  • Compare profiles across different conditions

• Phosphatase treatment controls:

  • Treat samples with lambda phosphatase to confirm phosphorylation-dependent mobility shifts

Research indicates that in wild-type cells, the phosphorylated form of ERV14 is approximately 35% less abundant than the non-phosphorylated form, while in the S134D mutant, the phosphorylated form is significantly reduced (to about 18%) .

Why might I detect multiple bands when immunoblotting for ERV14?

Multiple bands in ERV14 immunoblots can result from several factors:

• Post-translational modifications:

  • Phosphorylation at S134 causes mobility shifts detectable on Phos-tag gels

  • Research has confirmed at least two distinct ERV14 isoforms with different mobility

• Proteolytic processing:

  • Ensure samples are prepared with appropriate protease inhibitors

  • Compare band patterns across different extraction methods

• Epitope tag effects:

  • If using tagged versions (e.g., ERV14-HA), account for the increased molecular weight

  • Additional bands may appear with certain tagged constructs

• Antibody specificity:

  • Validate using Δerv14 controls

  • Compare patterns with different antibodies targeting different epitopes

To distinguish between these possibilities:

• Treat samples with phosphatase to eliminate phosphorylation-dependent bands

• Compare wild-type ERV14 with S134A and S134D mutants

• Use both tag-specific and ERV14-specific antibodies in parallel

How should I interpret conflicting data between biochemical and microscopy studies of ERV14 localization?

When facing discrepancies between biochemical fractionation and microscopy data:

• Consider methodological limitations:

  • Biochemical fractionation may not achieve complete separation of organelles

  • Microscopy resolution limits may obscure subtle localization differences

  • Fixation for immunofluorescence can alter protein localization

• Examine dynamic vs. steady-state distribution:

  • Fractionation provides a snapshot of steady-state distribution

  • Live imaging can capture dynamic trafficking events

  • Both approaches may be correct but capturing different aspects

• Quantitative analysis:

  • For fractionation, calculate the ratio of ERV14 in ER vs. Golgi fractions

  • For microscopy, measure colocalization coefficients with organelle markers

  • Compare quantitative measures across techniques

• Validate with complementary approaches:

  • In vitro vesicle budding assays to assess COPII packaging directly

  • Genetic interaction studies with secretory pathway components

  • Proximity labeling to identify interaction partners in different compartments

Research showing that ERV14 S134D exhibits altered localization (increased ER retention) in both fractionation and budding assays provides strong evidence that phosphorylation affects trafficking, even if microscopy might not detect subtle differences .

What is known about the kinases and phosphatases that regulate ERV14 phosphorylation?

Current research on the regulation of ERV14 phosphorylation is still developing:

• Kinases:

  • The specific kinases targeting S134 remain to be definitively identified

  • Bioinformatic analysis suggests this site matches consensus sequences for several kinases:

    • Casein kinase II (S/T-X-X-D/E motif)

    • Protein kinase C (S/T-X-R/K motif)

    • Cell cycle-dependent kinases (S/T-P-X-K/R motif)

• Phosphatases:

  • Research suggests a cycle of phosphorylation and dephosphorylation is important for ERV14 function

  • Candidates include PP1 and PP2A family phosphatases known to regulate membrane trafficking

• Regulatory significance:

  • Phosphorylation at S134 prevents incorporation of ERV14 into COPII vesicles

  • Phosphorylation affects cell growth and ER structure

  • The cycle of phosphorylation/dephosphorylation appears necessary for optimal ERV14 function

• Research approaches:

  • Kinase inhibitor screens to identify regulatory enzymes

  • Genetic screens using temperature-sensitive mutants

  • Co-immunoprecipitation to identify physical interactions

Further research using phospho-specific antibodies will be crucial to identify the regulatory enzymes and understand the temporal dynamics of ERV14 phosphorylation.

How does ERV14 phosphorylation impact its interactions with cargo proteins and COPII components?

ERV14 phosphorylation at S134 significantly alters its functional interactions:

• COPII coat interactions:

  • Phosphomimetic mutation (S134D) prevents incorporation of ERV14 into COPII vesicles

  • This suggests phosphorylation disrupts binding to COPII components

  • In vitro budding assays confirm reduced packaging of ERV14 S134D into vesicles

• Cargo protein interactions:

  • Phosphorylation affects localization of several plasma membrane transporters

  • This suggests altered cargo binding or transport capability

• Impact on genetic interactions:

  • ERV14 S134D exacerbates growth defects in sec23-1 and sec16-2 mutants

  • ERV14 S134D shows better growth with sec13-1 mutant, similar to Δerv14

  • These genetic interactions provide evidence for functional relationships with COPII components

• ER structure effects:

  • Both S134A and S134D mutations modify ER structure

  • This suggests phosphorylation affects broader membrane organization beyond direct protein interactions

The research indicates that phosphorylation serves as a regulatory switch, potentially allowing cells to control which cargo proteins are transported through the secretory pathway by modulating ERV14 function.

What novel approaches could identify additional phosphorylation sites on ERV14?

Future research to identify novel ERV14 phosphorylation sites should consider:

• Advanced mass spectrometry:

  • Phosphopeptide enrichment techniques (TiO₂, IMAC)

  • Parallel reaction monitoring for targeted analysis

  • Cross-linking mass spectrometry to identify interactions affected by phosphorylation

• Comprehensive mutagenesis:

  • Alanine scanning of all serine/threonine residues

  • Analysis of mobility shifts on Phos-tag gels

  • Functional testing using in vitro budding assays and genetic interactions

• Bioinformatic prediction followed by targeted validation:

  • Use phosphorylation site prediction algorithms

  • Create phosphomimetic mutations at predicted sites

  • Test effects on trafficking using established assays

• Proteomic comparison across conditions:

  • Analyze ERV14 phosphorylation during ER stress

  • Compare phosphorylation patterns across cell cycle stages

  • Examine changes in response to secretory pathway perturbations

While current research has identified S134 as a critical regulatory site , additional phosphorylation sites may contribute to the fine-tuning of ERV14 function in different cellular contexts.

How might ERV14 phosphorylation connect to broader cellular signaling networks?

Understanding the integration of ERV14 phosphorylation with cellular signaling networks represents an exciting frontier:

• Stress response pathways:

  • Investigation of how ER stress affects ERV14 phosphorylation status

  • Potential connections to the unfolded protein response (UPR)

  • Role in adaptive responses to secretory pathway overload

• Cell cycle regulation:

  • Analysis of ERV14 phosphorylation across cell cycle phases

  • Potential coordination with membrane growth and organelle inheritance

  • Connection to known cell cycle-regulated kinases

• Nutrient sensing:

  • Examination of ERV14 phosphorylation in response to nutrient availability

  • Potential coordination with TOR signaling

  • Role in regulating plasma membrane transporter localization

• Experimental approaches:

  • Phosphoproteomic analysis under various cellular conditions

  • Genetic interaction screens with signaling pathway components

  • Chemical genetic approaches using kinase inhibitors

These investigations could reveal how ERV14 phosphorylation serves as an integration point between cellular signaling and membrane trafficking, allowing cells to coordinate secretory pathway function with broader physiological states.